PTRA stands for Percutaneous Transluminal Renal Angioplasty. Renovascular hypertension is treated using percutaneous transluminal renal angioplasty, which is becoming a more popular peripheral vascular procedure. Charles Dotter created PTRA in 1964 to treat peripheral vascular atherosclerosis, which marked the beginning of catheter-based therapies. It is a cardiovascular ailment where blood circulation to the limbs is decreased due to constricted blood vessels. When Andreas Grüntzig created a soft, double-lumen flexible, balloon catheters to be used in coronary arteries in 1974, he completely changed the method. Since then, PTRA has quickly developed into a well-known, adaptable, and reliable vascular interventional procedure. If patients are carefully chosen and the treatment is carried out by skilled clinicians, excellent results can be obtained in the renal arteries.
Percutaneous transluminal renal angioplasty (PTRA), introduced in 1978, has become a highly successful method for treating renal artery stenosis (RAS). Renal angioplasty should be thought of as the treatment of preference for renovascular hypertension since it has significant physiological, psychological, and economic benefits over other treatment techniques. PTRA is being used more frequently as an option to surgical revascularization for treatment and management of RAS, which can result in hypertension or compromise renal function, either by itself or in conjunction with stent implantation. The technical success rate is often greater than 85%; the failure rate usually 10%.